Diabetes Health Type 1 & 2: Evaluating Mealtime Insulin Treatment Based on Needs and Insights

Sponsored by Lilly Diabetes

People work hard to manage their diabetes and yet, many still struggle to keep blood glucose levels in the target range.¹ In fact, according to research, those on intensive insulin treatment^*2 still spend more than 30 percent of the time above target blood glucose levels.³ This is of particular concern given the negative health consequences of high blood glucose, including elevated risk for long-term complications such as cardiovascular disease and diabetic retinopathy.⁴

 

As part of Lilly’s insulin development efforts, we undertook research to better understand the challenges that Americans and Britons living with type 1 diabetes and type 2 diabetes face in managing blood glucose levels on a daily basis. In that study, people treated with a mealtime insulin reported psychological, social, and work/school impacts and physical symptoms.⁵

 

At Lilly, we believe there is a need to look at a variety of outcomes– including managing blood glucose levels around mealtime – and develop treatment options to address them. Postprandial glucose (blood glucose levels following meals) is an important measure because it impacts, in part, overall A1C management.⁶ For people with diabetes who are not achieving their target A1C despite reaching their premeal glucose goals, measuring and treating postprandial glucose may help to lower their A1C.⁶

 

It is with these considerations in mind that we continue to invest in developing products that can better meet the diverse needs of people with diabetes. While insulin development has come a long way, many people with diabetes still struggle with a variety of outcomes, including meeting their target A1C. We hope that providing various insulin options can help people more effectively manage their diabetes.

 

We also understand that cost continues to be top of mind for many living with diabetes. For this reason, we want people who use Lilly insulins and need help affording their medicine to know that we’re here to support them. That’s why we have several affordability options dedicated to helping people with varying insurance circumstances, and individuals can call the Lilly Diabetes Solution Center at (833) 808-1234 to learn more.

 

Click here to learn more about a mealtime insulin option: https://e.lilly/2RA3yKq

*Intensive treatment defined in the Diabetes Control and Complications Trial as having a goal of normalization of blood glucose versus conventional treatment, which is defined as having the goal of clinical well-being.

PP-UR-US-0114 01/2021 ©Lilly USA, LLC 2021. All rights reserved.

References:

1. Runge, Ava S, et al. Does Time-in-Range Matter? Perspectives From People With Diabetes on the Success of Current Therapies and the Drivers of Improved Outcomes. Clin Diabetes, American Diabetes Association, Apr. 2018, ncbi.nlm.nih.gov/pmc/articles/PMC5898169/.
2. American Diabetes Association. Implications of the Diabetes Control and Complications Trial. Diabetes Care. 2003. 26(supl1): 25-27. https://doi.org/10.2337/diacare.26.2007.S25
3. Beck RW, Bergenstal RM, Riddlesworth TD, et al. Validation of Time in Range as an Outcome Measure for Diabetes Clinical Trials. Diabetes Care. 2019; 42(3):400‐405. https://doi.org/10.2337/dc18-1444
4. Mouri MI, Badireddy M. Hyperglycemia. Sept 2020. Available from: https://www.ncbi.nlm.nih.gov/books/NBK430900/
5. Poon JL, Gelhorn HL, et al. The Mealtime Insulin Experience: Symptoms and Impacts from the Patient Perspective. Presented at the American Association of Diabetes Educators (AADE) Annual Conference 2019; Aug 9-12.
6. American Diabetes Association. Postprandial Blood Glucose. Diabetes Care. 2001; 24(4):775-778. https://doi.org/10.2337/diacare.24.4.775